NewsBenzingaオクージェンは、バハマの規制当局からOCU400の暫定的な承認を受け、優先指定を受けました。同社はEAPを通じてOCU400を供給し、90日以内に最初のRP患者の治療を目指しています。 オクージェンは、バハマの規制当局からOCU400の暫定的な承認を受け、優先指定を受けました。同社はEAPを通じてOCU400を供給し、90日以内に最初のRP患者の治療を目指しています。 Benzinga 2026.09.25 11:13 (GMT+0) Open on Benzinga Other news Lumen Technologies Intends To Switch Common Stock Trading From NYSE To Nasdaq, Effective Oct. 5 Under Same Ticker Stephens & Co. Maintains Overweight on CarMax, Raises Price Target to $74 This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345 Raymond James Maintains Outperform on Axogen, Raises Price Target to $53 Jaguar Health Announces Issuance Of 182,091 Shares To Streeterville Capital For $1.67832M Reduction In 2021 Note Balance; 2025 Streeterville Note Fully Paid And Cancelled Following Exchange For 547,898 Shares
Lumen Technologies Intends To Switch Common Stock Trading From NYSE To Nasdaq, Effective Oct. 5 Under Same Ticker
This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345
Jaguar Health Announces Issuance Of 182,091 Shares To Streeterville Capital For $1.67832M Reduction In 2021 Note Balance; 2025 Streeterville Note Fully Paid And Cancelled Following Exchange For 547,898 Shares
